Walleye Capital LLC Beam Therapeutics Inc. Call Options Transaction History

Walleye Capital LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$23.46 - $45.07 $670,956 - $1.29 Million	-28,600 Reduced 94.08%	1,800 $59,000
Q4 2023 Feb 14, 2024	BUY	$17.69 - $30.76 $357,338 - $621,352	20,200 Added 198.04%	30,400 $827,000
Q3 2023 Nov 14, 2023	SELL	$23.01 - $32.46 $851,370 - $1.2 Million	-37,000 Reduced 78.39%	10,200 $245,000
Q2 2023 Aug 14, 2023	BUY	$29.32 - $35.99 $504,304 - $619,028	17,200 Added 57.33%	47,200 $1.51 Million
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $443,205 - $717,213	14,700 Added 96.08%	30,000 $918,000
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $62,440 - $87,720	1,700 Added 12.5%	15,300 $598,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $541,144 - $956,216	13,600 New	13,600 $648,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $2.04B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.